Characteristic | n (%) | Geometric Mean Titres¥ (95% CI) |
---|---|---|
Age groups in years | Â | Â |
 16–29* | 267 (17.6%) | 1470 (1286–1679) |
 30–39 | 425 (28.0%) | 1112 (986–1256) |
 40–49 | 360 (23.7%) | 1319 (1151–1513) |
 50–59 | 338 (22.3%) | 1423 (1275–1589) |
 60+ | 99 (6.5%) | 1756 (1477–2087) |
 Unknown | 28 (1.8%) | 833 (466–1487) |
Gender | Â | Â |
 Female | 1112 (73.3%) | 1344 (1251–1445) |
 Male | 397 (26.2%) | 1233 (1105–1377) |
 Non-Binary | 4 (0.3%) | 1769 (1131–2766) |
 Unknown | 4 (0.3%) | 2167 (658–7134) |
Previous laboratory-confirmed SARS-CoV-2 infection | Â | Â |
 Yes, once | 214 (14.1%) | 1487 (1265–1747) |
 Yes, > 1 reinfection | 11 (0.7%) | 1776 (970–3251) |
Time since previous laboratory confirmed SARS-CoV-2 infection | Â | Â |
 ≤ 3 months | 58 (3.8%) | 1507 (1103–2059) |
 > 3 months | 153 (10.1%) | 1524 (1270–1829) |
 unknown | 14 (0.9%) | 1227 (468–3220) |
 No | 1284 (84.6%) | 1285 (1203–1372) |
 Unknown | 8 (0.5%) | 1845 (937–3630) |
Type of profession | Â | Â |
 Nurse | 467 (30.8%) | 1309 (1167–1468) |
 Physician | 262 (17.3%) | 1278 (1144–1428) |
 Other allied health professionals | 402 (26.5%) | 1382 (1229–1555) |
 Administration/other facility management | 364 (24.0%) | 1272 (1117–1449) |
 Unknown | 22 (1.5%) | 1577 (879–2829) |
Number of vaccine doses received | Â | Â |
 Three times vaccinated (plus evidence of past SARS-CoV-2 infection) | 79 (5.2%) | 2204 (1919–2531) |
 Three times vaccinated (no evidence of past SARS-CoV-2 infection) | 1122 (74.0%) | 1650 (1585–1717) |
 Two times vaccinated (plus evidence of past SARS-CoV-2 infection) | 98 (6.5%) | 1755 (1433–2150) |
 Two times vaccinated (no evidence of past SARS-CoV-2 infection) | 101 (6.7%) | 335 (258–434) |
 One time vaccinated (plus evidence of past SARS-CoV-2 infection)** | 32 (2.1%) | 1059 (713–1573) |
 One time vaccinated (no evidence of past SARS-CoV-2 infection)*** | 19 (1.3%) | 394 (132–1176) |
 Not vaccinated (plus evidence of past SARS-CoV-2 infection) | 16 (1.1%) | 171 (61–475) |
 Not vaccinated (no evidence of past SARS-CoV-2 infection) | 42 (2.8%) | 69 (26–184) |
 Unknown | 8 (0.5%) | 1845 (937–3630) |
Combined SARS-CoV-2 vaccination and past infection exposures | Â | Â |
 None | 42 (2.8%) | 69 (26–184) |
 One exposure | 34 (2.3%) | 272 (128–578) |
 Two exposures | 133 (8.8%) | 435 (345–549) |
 Three exposures | 1217 (80.6%) | 1655 (1590–1722) |
 Four exposures | 79 (5.2%) | 2260 (1962–2602) |
 Five exposures | 4 (0.3%) | 2043 (1366–3056) |
Type of specific vaccination received (among those three times vaccinated) | N = 1201 |  |
 2 doses BNT162b2 (3 weeks apart) + BNT162b2 booster | 436 (36.3%) | 1629 (1530–1734) |
 2 doses BNT162b2 (6 weeks apart) + BNT162b2 booster | 130 (10.8%) | 2008 (1761–2291) |
 1 dose ChAdOx1-S, 1 dose BNT162b2 + BNT162b2 booster | 378 (31.5%) | 1576 (1478–1681) |
 2 doses ChAdOx1-S + BNT162b2 booster | 159 (13.2%) | 1699 (1505–1918) |
 1 dose ChAdOx1-S, 1 dose BNT162b2 + mRNA-1273 booster | 23 (1.9%) | 2154 (1788–2595) |
 2 doses mRNA-1273 + BNT162b2 booster | 11 (0.9%) | 1733 (1305–2300) |
 2 doses BNT162b2 + mRNA-1273 booster | 11 (0.9%) | 3343 (2311–4837) |
 2 doses ChAdOx1-S + mRNA-1273 booster | 11 (0.9%) | 3502 (2338–5246) |
 Unknown/other vaccine scheme | 42 (3.5%) | 1472 (1244–1741) |
Type of vaccination scheme received (among those three times vaccinated) | Â | Â |
 Homologous COVID-19 vaccine scheme | 566 (47.1%) | 1710 (1615–1810) |
 Heterologous COVID-19 vaccine scheme with mRNA-1273 booster | 45 (3.7%) | 2657 (2267–3114) |
 Heterologous COVID-19 vaccine scheme with another booster | 548 (45.6%) | 1614 (1525–1709) |
Time since last COVID-19 vaccine dose (among those three times vaccinated) | N = 1201 |  |
 < 30 days | 78 (6.5%) | 2151 (1698–2724) |
 30–49 days | 586 (48.8%) | 1877 (1786–1971) |
 50–69 days | 299 (24.9%) | 1627 (1510–1754) |
 70–89 days | 170 (14.2%) | 1324 (1200–1461) |
 ≥ 90 days | 37 (3.1%) | 1156 (876–1524) |
 Unknown | 31 (2.6%) | 1249 (857–1821) |